RxDoctor Payments Data

Anatoly Bulkin, MD

Vascular Surgery · Escondido, CANPI 1275593154

Payments from drug & device makers

$44,574in general payments, 2019–2025

Across 524 payments — averaging $85.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$25K
  • BD$3K
  • Penumbra, Inc.$2K
  • Musculoskeletal Transplant Foundation Inc.$2K
  • Organogenesis Inc.$1K
  • Johnson & Johnson$1K
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$5,09311%
  • Travel & lodging$8732%
  • Food & beverage$13,48130%
  • Education$3811%
  • Other$24,74656%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,574 in reported general payments places this provider in the 85th percentile of 519 vascular surgery providers in California.

See all vascular surgery providers in California

Medicare billing

Part B allowed, 2024
$983,207
Medicare patients
535
Services billed
4,886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban148$162,789
EliquisApixaban126$151,177
OzempicSemaglutide13$12,080
Repatha SureclickEvolocumab14$7,731
Daptomycin12$6,621
Prasugrel Hcl39$5,525
ClopidogrelClopidogrel Bisulfate88$1,160
Cilostazol34$805
Simvastatin77$801
Doxycycline Hyclate42$658
SsdSilver Sulfadiazine53$609
Gabapentin50$447
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav25$363
Ciprofloxacin Hcl41$347
Pentoxifylline15$272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$1,237$162,789148 claims
PfizerEliquis$257$151,177126 claims
Novo NordiskOzempic$71$12,08013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 519 vascular surgery providers in California.

Other vascular surgery in Escondido

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →